First-in-Class Diagnostics

We are raising a seed round to secure intellectual property, complete clinical validation, and accelerate the development of our first-in-class diagnostic platform for gluten-associated diseases. Despite affecting millions worldwide, current diagnostic solutions are slow, unreliable, or unavailable — leaving patients and healthcare providers without effective tools for early detection and management.

With IP protection underway, we are now focused on final validation studies, regulatory preparation, and strategic partnerships to enable a fast market entry.

The seed funding will allow us to build the foundation for scale: strengthening our IP portfolio, advancing product development, and positioning the company for Series A and beyond.